Quarterly report · Q2
4544.TEDINET S100S6Z0
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥116.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥260.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥134.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥17.7bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.8bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥20.7bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥284.6bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥297.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥287.2bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥134.4bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥147.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥150.1bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥150.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥157.2bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥37.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥44.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥37.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥44.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥37.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥5.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥32.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥7.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥29.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥18.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥7.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-32 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.33 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥275.52 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥273.87 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥175.63 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥275.5 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥273.84 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 52.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.7% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥3.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥3.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥2.8bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥72.4bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥72.3bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥74m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥6.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥33.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥30.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥564m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥119.6bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥116.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥5.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥5.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.5bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥85.1bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥85.0bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥83m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.9bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥40.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥35.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥15.7bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥604m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥139.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥134.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥19.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 524
| Item | Context | Value | Unit |
|---|---|---|---|
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding reduction entry (text) | CurrentQuarterInstant | Text · Plus | |
| Notes regarding guarantee obligations (text) | CurrentQuarterInstant | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentQuarterInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding gain on step acquisitions (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding gain on transfer of business (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding loss on valuation of other investments (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |